s13104-018-3391-9.pdf (1.6 MB)
Download file

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.

Download (1.6 MB)
journal contribution
posted on 16.05.2018, 14:24 by Afaf Alharthi, Daniel Beck, Dena R. Howard, Peter Hillmen, Melanie Oates, Andrew Pettitt, Simon D. Wagner
OBJECTIVES: In vitro culture studies have shown that miR-363 is enriched in extracellular vesicles from chronic lymphocytic leukaemia cells. We wondered whether miR-363 was detectable in plasma, which is an essential precondition for further studies to assess its usefulness as a biomarker. Using samples from two clinical trials: one enrolling patients with advanced disease and the other asymptomatic patients with early stage disease, we determined plasma miR-363 levels and secondly investigated the distribution of this miRNA between plasma and particle bound fractions in patients and normal subjects. RESULTS: Advanced disease (n = 95) was associated with higher levels of miR-363 than early stage disease (n = 45) or normal subjects (n = 11) but there was no association with markers of prognosis. The distribution of specific miRNA between particle bound and plasma protein fractions was investigated using size exclusion chromatography on plasma from patients (n = 4) and normal subjects (n = 3). ~ 20% of total miR-16 and miR-363 is particle bound in patients while there was no detectable particle bound material in normal subjects. Our work demonstrates that miR-363 levels are raised in chronic lymphocytic leukaemia patients and raises the possibility that distribution of circulating miRNA between plasma fractions differs in health and disease.

Funding

PhD studentship from the government of Saudi Arabia to AA. The UK CLL Trials Biobank, University of Liverpool is funded by Bloodwise. ARCTIC clinical trial funded by the NIHR Health Technology Assessment Programme (NIHR HTA Project Number 07/01/38; ISRCTN16544962).

History

Citation

BMC Research Notes, 2018, 11:280

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Cancer Research Centre

Version

VoR (Version of Record)

Published in

BMC Research Notes

Publisher

BioMed Central

eissn

1756-0500

Acceptance date

03/05/2018

Copyright date

2018

Available date

16/05/2018

Publisher version

https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-018-3391-9

Notes

The data that support the findings from the ARCTIC clinical trial (Reference 19) are available from the Leeds Clinical Trials Unit but restrictions apply to the availability of these data, which were used following completion of a Data Sharing Agreement between the universities of Leeds and Leicester and so are not publicly available. All other data generated or analysed during this study are included in this published article.

Language

en

Usage metrics

Categories

Licence

Exports